SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Sillence DO, Senn A, Danks DM 1979 Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 16: 101116.
  • 2
    Glorieux FH, Travers R, Taylor A, Bowen JR, Rauch F, Norman M, Parfitt AM 2000 Normative data for iliac bone histomorphometry in growing children. Bone 26: 103109.
  • 3
    Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R 1998 Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339: 947952.
  • 4
    Astrom A, Soderhall S 2002 Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 86: 356364.
  • 5
    Zacharin M, Bateman J 2002 Pamidronate treatment of osteogenesis imperfecta-lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response. J Pediatr Endocrinol Metab 15: 163174.
  • 6
    Rauch F, Travers R, Plotkin H, Glorieux FH 2002 The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 110: 12931299.
  • 7
    Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, Glorieux FH 2000 Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 85: 18461850.
  • 8
    Astrom E, Soderhall S 2002 Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 86: 356364.
  • 9
    Chien YH, Chu SY, Hsu CC, Hwu WL 2002 Pamidronate treatment of severe osteogenesis imperfecta in a newborn infant. J Inherit Metab Dis 25: 593595.
  • 10
    Falk MJ, Heeger S, Lynch KA, DeCaro KR, Bohach D, Gibson KS, Warman ML 2003 Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics 111: 573578.
  • 11
    DiMeglio LA, Ford L, McClintock C, Peacock M 2004 Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. Bone 35: 10381045.
  • 12
    Zeitlin L, Fassier F, Glorieux FH 2003 Modern approach to children with osteogenesis imperfecta. J Pediatr Orthop B 12: 7787.
  • 13
    Feldman AB, Haley SM, Coryell J 1990 Concurrent and construct validity of the Pediatric Evaluation of Disability Inventory. Phys Ther 70: 602610.
  • 14
    Bleck EE 1981 Nonoperative treatment of osteogenesis imperfecta: Orthotic and mobility management. Clin Orthop 159: 111122.
  • 15
    Greulich WW, Pyle SI 1959 Radiographic Atlas of Skeletal Development of the Hand and Wrist, 2nd ed. Stanford University Press, Stanford, CA, USA.
  • 16
    Spencer RP, Sagel SS, Garn SM 1968 Age changes in five parameters of metacarpal growth. Invest Radiol 3: 2734.
  • 17
    Smith-Bindman R, Cummings SR, Steiger P, Genant HK 1991 A comparison of morphometric definitions of vertebral fracture. J Bone Miner Res 6: 2534.
  • 18
    Salle BL, Braillon P, Glorieux FH, Brunet J, Cavero E, Meunier PJ 1992 Lumbar bone mineral content measured by dual energy X-ray absorptiometry in newborns and infants. Acta Paediatr 81: 953958.
  • 19
    Rauch F, Plotkin H, Zeitlin L, Glorieux FH 2003 Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: Effect of intravenous pamidronate therapy. J Bone Miner Res 18: 610614.
  • 20
    Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH 2003 Osteogenesis imperfecta types I, III and IV: Effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab 88: 986992.
  • 21
    Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2: 595610.
  • 22
    Fazzalari NL, Moore AJ, Byers S, Byard RW 1997 Quantitative analysis of trabecular morphogenesis in the human costochondral junction during the postnatal period in normal subjects. Anat Rec 248: 112.
  • 23
    Mayahara M, Sasaki T 2003 Cellular mechanism of inhibition of osteoclastic resorption of bone and calcified cartilage by long-term pamidronate administration in ovariectomized mature rats. Anat Rec 274A: 817826.
  • 24
    Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S 2003 Bisphosphonate-induced osteopetrosis. N Engl J Med 349: 457463.
  • 25
    Halasy-Nagy JM, Rodan GA, Reszka AA 2001 Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone 29: 553559.
  • 26
    Munns CF, Rauch F, Mier RJ, Glorieux FH 2004 Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone 35: 231234.
  • 27
    Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB 2000 Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15: 613620.